Dalbavancin
From Wikipedia, the free encyclopedia
 |
|
|
Dalbavancin
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C88H100Cl2N10O28 |
| Mol. mass | 1755.634 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous |
Dalbavancin, a novel second-generation lipoglycopeptide agent, belongs to the same class as vancomycin, the most widely-used and one of the few treatments available to patients infected with MRSA.[1]
It possesses in vitro activity against a variety of gram-positive pathogens[2][3] including MRSA and MRSE. [4]It is a once-weekly, two-dose antibiotic that Pfizer acquired when it bought Vicuron Pharmaceuticals in 2005.[5]
[edit] References and notes
- ^ Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration
- ^ Chen AY, Zervos MJ, Vazquez JA (2007). "Dalbavancin: a novel antimicrobial". Int. J. Clin. Pract. 61 (5): 853–63. doi:. PMID 17362476.
- ^ Das B, Sarkar C, Biswas R, Pandey S (2008). "Review: dalbavancin-a novel lipoglycopeptide antimicrobial for gram positive pathogens". Pak J Pharm Sci 21 (1): 78–88. PMID 18166524.
- ^ Dalbavancin: A Novel Lipoglycopeptide Antibacterial
- ^ UPDATE 1-Pfizer says US FDA wants more data on antibiotic
|
||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
